JP2015500212A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015500212A5 JP2015500212A5 JP2014543747A JP2014543747A JP2015500212A5 JP 2015500212 A5 JP2015500212 A5 JP 2015500212A5 JP 2014543747 A JP2014543747 A JP 2014543747A JP 2014543747 A JP2014543747 A JP 2014543747A JP 2015500212 A5 JP2015500212 A5 JP 2015500212A5
- Authority
- JP
- Japan
- Prior art keywords
- carbonyl
- phthalazin
- fluoro
- piperazine
- phenoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 chloro, fluoro, bromo, iodo Chemical group 0.000 claims 37
- IJAPPYDYQCXOEF-UHFFFAOYSA-N phthalazin-1(2H)-one Chemical compound C1=CC=C2C(=O)NN=CC2=C1 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 239000012453 solvate Substances 0.000 claims 11
- 125000005842 heteroatom Chemical group 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- 125000003302 alkenyloxy group Chemical group 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- 150000002431 hydrogen Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- QNKQLZIDPHLSLX-UHFFFAOYSA-N 4-[3-[4-(1-aminocyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CCN1C(=O)C1(N)CC1 QNKQLZIDPHLSLX-UHFFFAOYSA-N 0.000 claims 2
- TVWIYKCKCUIDFX-UHFFFAOYSA-N 4-[3-[4-(2,2-dimethylpropanoyl)piperazine-1-carbonyl]-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(=O)C(C)(C)C)CCN1C(=O)C1=CC(OC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F TVWIYKCKCUIDFX-UHFFFAOYSA-N 0.000 claims 2
- IJSAVXZCXLCXRP-UHFFFAOYSA-N 4-[3-[4-(2-ethylbutanoyl)piperazine-1-carbonyl]-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(=O)C(CC)CC)CCN1C(=O)C1=CC(OC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F IJSAVXZCXLCXRP-UHFFFAOYSA-N 0.000 claims 2
- PGOSXGKZYJLWAN-UHFFFAOYSA-N 4-[3-[4-[1-(dimethylamino)cyclobutanecarbonyl]piperazine-1-carbonyl]-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CCN1C(=O)C1(N(C)C)CCC1 PGOSXGKZYJLWAN-UHFFFAOYSA-N 0.000 claims 2
- XDVCDFIVFSEAIF-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(2-nitrobenzoyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound [O-][N+](=O)C1=CC=CC=C1C(=O)N1CCN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CC1 XDVCDFIVFSEAIF-UHFFFAOYSA-N 0.000 claims 2
- BCFBHNMOIFYWBS-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(piperidine-1-carbonyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)N1CCCCC1 BCFBHNMOIFYWBS-UHFFFAOYSA-N 0.000 claims 2
- PHEJNKZPYQUXHV-UHFFFAOYSA-N 4-[4-fluoro-3-[4-[1-(methylamino)cyclobutanecarbonyl]piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CCN1C(=O)C1(NC)CCC1 PHEJNKZPYQUXHV-UHFFFAOYSA-N 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- TUWZZXGAUMSUOB-UHFFFAOYSA-N benzyl piperidine-1-carboxylate Chemical compound C1CCCCN1C(=O)OCC1=CC=CC=C1 TUWZZXGAUMSUOB-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- IDXLYJQVIRPLDQ-UHFFFAOYSA-N 2-[4-[2-fluoro-5-[(4-oxo-3h-phthalazin-1-yl)oxy]benzoyl]piperazine-1-carbonyl]benzonitrile Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1=CC=CC=C1C#N IDXLYJQVIRPLDQ-UHFFFAOYSA-N 0.000 claims 1
- ZQTXNSWUYNTEBB-UHFFFAOYSA-N 2-[4-fluoro-3-[4-(2-methoxyacetyl)piperazine-1-carbonyl]phenoxy]phthalazin-1-one Chemical compound FC1=C(C=C(ON2C(C3=CC=CC=C3C=N2)=O)C=C1)C(=O)N1CCN(CC1)C(COC)=O ZQTXNSWUYNTEBB-UHFFFAOYSA-N 0.000 claims 1
- WAQCRMFLOXJEPH-UHFFFAOYSA-N 2-[4-fluoro-3-[4-(2-methyl-1,3-thiazole-4-carbonyl)piperazine-1-carbonyl]phenoxy]phthalazin-1-one Chemical compound FC1=C(C=C(ON2C(C3=CC=CC=C3C=N2)=O)C=C1)C(=O)N1CCN(CC1)C(=O)C=1N=C(SC=1)C WAQCRMFLOXJEPH-UHFFFAOYSA-N 0.000 claims 1
- YUNMCHVYEFMZIE-UHFFFAOYSA-N 2-[4-fluoro-3-[4-(5-methyl-1,2-oxazole-4-carbonyl)piperazine-1-carbonyl]phenoxy]phthalazin-1-one Chemical compound FC1=C(C=C(ON2C(C3=CC=CC=C3C=N2)=O)C=C1)C(=O)N1CCN(CC1)C(=O)C=1C=NOC=1C YUNMCHVYEFMZIE-UHFFFAOYSA-N 0.000 claims 1
- MUWUCBFFVDRMOQ-UHFFFAOYSA-N 2-phenoxyphthalazin-1-one Chemical compound O(C1=CC=CC=C1)N1C(C2=CC=CC=C2C=N1)=O MUWUCBFFVDRMOQ-UHFFFAOYSA-N 0.000 claims 1
- MCVFOGMCFOGZNE-UHFFFAOYSA-N 3-[4-[2-fluoro-5-[(4-oxo-3h-phthalazin-1-yl)oxy]benzoyl]piperazine-1-carbonyl]benzonitrile Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1=CC=CC(C#N)=C1 MCVFOGMCFOGZNE-UHFFFAOYSA-N 0.000 claims 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims 1
- OXZAGDCIHSWPSQ-UHFFFAOYSA-N 4-[3-(4-acetylpiperazine-1-carbonyl)-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(=O)C)CCN1C(=O)C1=CC(OC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F OXZAGDCIHSWPSQ-UHFFFAOYSA-N 0.000 claims 1
- RSJQQCASEGSQDI-UHFFFAOYSA-N 4-[3-(4-benzoylpiperazine-1-carbonyl)-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1=CC=CC=C1 RSJQQCASEGSQDI-UHFFFAOYSA-N 0.000 claims 1
- LITWQHBVWSJKPY-UHFFFAOYSA-N 4-[3-(4-benzoylpiperazine-1-carbonyl)-4-fluorophenoxy]-5-chloro-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=C(Cl)C=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1=CC=CC=C1 LITWQHBVWSJKPY-UHFFFAOYSA-N 0.000 claims 1
- FEOUWECRHACLNJ-UHFFFAOYSA-N 4-[3-(4-benzoylpiperazine-1-carbonyl)-4-fluorophenoxy]-5-nitro-2h-phthalazin-1-one Chemical compound [O-][N+](=O)C1=CC=CC(C(NN=2)=O)=C1C=2OC(C=1)=CC=C(F)C=1C(=O)N(CC1)CCN1C(=O)C1=CC=CC=C1 FEOUWECRHACLNJ-UHFFFAOYSA-N 0.000 claims 1
- QGDDDEOCEHOXKJ-UHFFFAOYSA-N 4-[3-(4-tert-butylpiperazine-1-carbonyl)-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(C)(C)C)CCN1C(=O)C1=CC(OC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F QGDDDEOCEHOXKJ-UHFFFAOYSA-N 0.000 claims 1
- ZJSQULBIGVRLSV-UHFFFAOYSA-N 4-[3-[4-(1-aminocyclobutanecarbonyl)piperazine-1-carbonyl]-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CCN1C(=O)C1(N)CCC1 ZJSQULBIGVRLSV-UHFFFAOYSA-N 0.000 claims 1
- UFVPUCUXFUEIDV-UHFFFAOYSA-N 4-[3-[4-(2-cyclopentylacetyl)piperazine-1-carbonyl]-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)CC1CCCC1 UFVPUCUXFUEIDV-UHFFFAOYSA-N 0.000 claims 1
- RWQBQENZPPMPPI-UHFFFAOYSA-N 4-[3-[4-(2-cyclopropylacetyl)piperazine-1-carbonyl]-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)CC1CC1 RWQBQENZPPMPPI-UHFFFAOYSA-N 0.000 claims 1
- SKGRPBVRUGLOSF-UHFFFAOYSA-N 4-[3-[4-(2-ethoxyacetyl)piperazine-1-carbonyl]-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(=O)COCC)CCN1C(=O)C1=CC(OC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F SKGRPBVRUGLOSF-UHFFFAOYSA-N 0.000 claims 1
- QJQDIQKTDSBMOB-UHFFFAOYSA-N 4-[3-[4-(4,4-difluorocyclohexanecarbonyl)piperazine-1-carbonyl]-4-fluorophenoxy]-2H-phthalazin-1-one Chemical compound Fc1ccc(Oc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CCC(F)(F)CC1 QJQDIQKTDSBMOB-UHFFFAOYSA-N 0.000 claims 1
- SSVOKXAGBNLVLQ-UHFFFAOYSA-N 4-[3-[4-(4,4-difluoropiperidine-1-carbonyl)piperazine-1-carbonyl]-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)N1CCC(F)(F)CC1 SSVOKXAGBNLVLQ-UHFFFAOYSA-N 0.000 claims 1
- IWLJMCXJVVOBBW-UHFFFAOYSA-N 4-[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 IWLJMCXJVVOBBW-UHFFFAOYSA-N 0.000 claims 1
- DZWVGXKLZPKLKS-UHFFFAOYSA-N 4-[3-[4-[1-(dimethylamino)cyclopropanecarbonyl]piperazine-1-carbonyl]-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CCN1C(=O)C1(N(C)C)CC1 DZWVGXKLZPKLKS-UHFFFAOYSA-N 0.000 claims 1
- YGXNDLBTQGMPOV-UHFFFAOYSA-N 4-[3-[4-[3-(dimethylamino)benzoyl]piperazine-1-carbonyl]-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound CN(C)C1=CC=CC(C(=O)N2CCN(CC2)C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)=C1 YGXNDLBTQGMPOV-UHFFFAOYSA-N 0.000 claims 1
- NDEWUMPGCMVIOL-UHFFFAOYSA-N 4-[3-[4-[4-(dimethylamino)benzoyl]piperazine-1-carbonyl]-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound C1=CC(N(C)C)=CC=C1C(=O)N1CCN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CC1 NDEWUMPGCMVIOL-UHFFFAOYSA-N 0.000 claims 1
- ZSHQAWHQMUOABD-UHFFFAOYSA-N 4-[4-[2-fluoro-5-[(4-oxo-3h-phthalazin-1-yl)oxy]benzoyl]piperazine-1-carbonyl]benzonitrile Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1=CC=C(C#N)C=C1 ZSHQAWHQMUOABD-UHFFFAOYSA-N 0.000 claims 1
- YJMHEEGVFDLUFN-UHFFFAOYSA-N 4-[4-fluoro-3-(4-methylpiperazine-1-carbonyl)phenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C)CCN1C(=O)C1=CC(OC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F YJMHEEGVFDLUFN-UHFFFAOYSA-N 0.000 claims 1
- PXYIFDVNUHAHEH-UHFFFAOYSA-N 4-[4-fluoro-3-(4-prop-2-enoylpiperazine-1-carbonyl)phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N1CCN(C(=O)C=C)CC1 PXYIFDVNUHAHEH-UHFFFAOYSA-N 0.000 claims 1
- PWJANPHHJVLKFB-UHFFFAOYSA-N 4-[4-fluoro-3-(piperazine-1-carbonyl)phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N1CCNCC1 PWJANPHHJVLKFB-UHFFFAOYSA-N 0.000 claims 1
- LDYIPKQZQAIRTD-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(1,3-thiazole-4-carbonyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1=CSC=N1 LDYIPKQZQAIRTD-UHFFFAOYSA-N 0.000 claims 1
- XMXROHYJWCZPPL-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(2,2,2-trifluoroacetyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N1CCN(C(=O)C(F)(F)F)CC1 XMXROHYJWCZPPL-UHFFFAOYSA-N 0.000 claims 1
- NGRBLFZCOQNFEU-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(2-hydroxyethyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1CN(CCO)CCN1C(=O)C1=CC(OC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F NGRBLFZCOQNFEU-UHFFFAOYSA-N 0.000 claims 1
- VODHOJPJFWVPHK-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(2-hydroxypropanoyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(=O)C(O)C)CCN1C(=O)C1=CC(OC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F VODHOJPJFWVPHK-UHFFFAOYSA-N 0.000 claims 1
- MVYFDNKSMQLYJP-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(2-methylpropanoyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(=O)C(C)C)CCN1C(=O)C1=CC(OC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F MVYFDNKSMQLYJP-UHFFFAOYSA-N 0.000 claims 1
- ZNXUITMOKZZDLO-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(3,3,3-trifluoropropanoyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N1CCN(C(=O)CC(F)(F)F)CC1 ZNXUITMOKZZDLO-UHFFFAOYSA-N 0.000 claims 1
- DSBUUJLGVNOCFI-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(3-nitrobenzoyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound [O-][N+](=O)C1=CC=CC(C(=O)N2CCN(CC2)C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)=C1 DSBUUJLGVNOCFI-UHFFFAOYSA-N 0.000 claims 1
- GXQGLXCMWVOQCQ-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(4-fluorobenzoyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1=CC(F)=CC=C1C(=O)N1CCN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CC1 GXQGLXCMWVOQCQ-UHFFFAOYSA-N 0.000 claims 1
- ZVASRUFHGODWNV-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(4-fluorobenzoyl)piperazine-1-carbonyl]phenoxy]-5-nitro-2h-phthalazin-1-one Chemical compound [O-][N+](=O)C1=CC=CC(C(NN=2)=O)=C1C=2OC(C=1)=CC=C(F)C=1C(=O)N(CC1)CCN1C(=O)C1=CC=C(F)C=C1 ZVASRUFHGODWNV-UHFFFAOYSA-N 0.000 claims 1
- JYULXMCNNAMJSH-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(4-fluorophenyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1=CC(F)=CC=C1N1CCN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CC1 JYULXMCNNAMJSH-UHFFFAOYSA-N 0.000 claims 1
- STZWABPGYDHYHM-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(4-fluorophenyl)piperazine-1-carbonyl]phenoxy]-5-nitro-2h-phthalazin-1-one Chemical compound [O-][N+](=O)C1=CC=CC(C(NN=2)=O)=C1C=2OC(C=1)=CC=C(F)C=1C(=O)N(CC1)CCN1C1=CC=C(F)C=C1 STZWABPGYDHYHM-UHFFFAOYSA-N 0.000 claims 1
- JTZDUKTYNORBQE-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(4-nitrobenzoyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(=O)N1CCN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CC1 JTZDUKTYNORBQE-UHFFFAOYSA-N 0.000 claims 1
- MYMOJTQDIFCGBT-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(4-nitrobenzoyl)piperazine-1-carbonyl]phenoxy]-5-nitro-2h-phthalazin-1-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(=O)N1CCN(C(=O)C=2C(=CC=C(OC=3C4=C([N+]([O-])=O)C=CC=C4C(=O)NN=3)C=2)F)CC1 MYMOJTQDIFCGBT-UHFFFAOYSA-N 0.000 claims 1
- AWJBJIJKZWTVPH-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(4-oxocyclohexanecarbonyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CCC(=O)CC1 AWJBJIJKZWTVPH-UHFFFAOYSA-N 0.000 claims 1
- DSBVAGDGCREERF-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(5-methyl-1,2-oxazole-3-carbonyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound O1C(C)=CC(C(=O)N2CCN(CC2)C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)=N1 DSBVAGDGCREERF-UHFFFAOYSA-N 0.000 claims 1
- NUSRLLJEWPPZLY-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(furan-2-carbonyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1=CC=CO1 NUSRLLJEWPPZLY-UHFFFAOYSA-N 0.000 claims 1
- MZUSFLMKFYNSLH-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(morpholine-4-carbonyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)N1CCOCC1 MZUSFLMKFYNSLH-UHFFFAOYSA-N 0.000 claims 1
- PJBCOLGZCWHQBM-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(pyrazole-1-carbonyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)N1C=CC=N1 PJBCOLGZCWHQBM-UHFFFAOYSA-N 0.000 claims 1
- GTOVJKQDZATUTM-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(pyridine-4-carbonyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1=CC=NC=C1 GTOVJKQDZATUTM-UHFFFAOYSA-N 0.000 claims 1
- IAEWYDVKRXZOBF-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(pyrrolidine-1-carbonyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)N1CCCC1 IAEWYDVKRXZOBF-UHFFFAOYSA-N 0.000 claims 1
- XKGULLZXZMMSTK-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(pyrrolidine-2-carbonyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CCCN1 XKGULLZXZMMSTK-UHFFFAOYSA-N 0.000 claims 1
- CHKWKJRVIKDBSS-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(thiophene-2-carbonyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1=CC=CS1 CHKWKJRVIKDBSS-UHFFFAOYSA-N 0.000 claims 1
- BTWJXXSFLYVKGY-RUZDIDTESA-N 4-[4-fluoro-3-[4-[(2r)-2-methylpyrrolidine-2-carbonyl]piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CCN1C(=O)[C@@]1(C)CCCN1 BTWJXXSFLYVKGY-RUZDIDTESA-N 0.000 claims 1
- WSYWPHSFOFNAPL-GOSISDBHSA-N 4-[4-fluoro-3-[4-[(2r)-2-phenylpropanoyl]piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1([C@H](C(=O)N2CCN(CC2)C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)C)=CC=CC=C1 WSYWPHSFOFNAPL-GOSISDBHSA-N 0.000 claims 1
- ITKLIXNMDWZJLG-UHFFFAOYSA-N 4-[4-fluoro-3-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CC1 ITKLIXNMDWZJLG-UHFFFAOYSA-N 0.000 claims 1
- HNYXUAMLVLTDBI-UHFFFAOYSA-N 4-[4-fluoro-3-[4-[1-(methylamino)cyclopropanecarbonyl]piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CCN1C(=O)C1(NC)CC1 HNYXUAMLVLTDBI-UHFFFAOYSA-N 0.000 claims 1
- WHLJSEGNUSKGDC-UHFFFAOYSA-N 4-[4-fluoro-3-[4-[4-(trifluoromethyl)benzoyl]piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1=CC=C(C(F)(F)F)C=C1 WHLJSEGNUSKGDC-UHFFFAOYSA-N 0.000 claims 1
- DVBCKRUUPXUPJY-UHFFFAOYSA-N 4-[4-fluoro-3-[4-[4-methyl-3-(trifluoromethyl)benzoyl]piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1=C(C(F)(F)F)C(C)=CC=C1C(=O)N1CCN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CC1 DVBCKRUUPXUPJY-UHFFFAOYSA-N 0.000 claims 1
- KYGOXTUMVZLTJB-UHFFFAOYSA-N 5-chloro-4-[4-fluoro-3-[4-(4-fluorobenzoyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1=CC(F)=CC=C1C(=O)N1CCN(C(=O)C=2C(=CC=C(OC=3C4=C(Cl)C=CC=C4C(=O)NN=3)C=2)F)CC1 KYGOXTUMVZLTJB-UHFFFAOYSA-N 0.000 claims 1
- DINVORPPFQVLCT-UHFFFAOYSA-N 5-chloro-4-[4-fluoro-3-[4-(4-fluorophenyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1=CC(F)=CC=C1N1CCN(C(=O)C=2C(=CC=C(OC=3C4=C(Cl)C=CC=C4C(=O)NN=3)C=2)F)CC1 DINVORPPFQVLCT-UHFFFAOYSA-N 0.000 claims 1
- VQHPTVHDNVWZCW-UHFFFAOYSA-N 5-chloro-4-[4-fluoro-3-[4-(4-nitrobenzoyl)piperazine-1-carbonyl]phenoxy]-2H-phthalazin-1-one Chemical compound [O-][N+](=O)c1ccc(cc1)C(=O)N1CCN(CC1)C(=O)c1cc(Oc2n[nH]c(=O)c3cccc(Cl)c23)ccc1F VQHPTVHDNVWZCW-UHFFFAOYSA-N 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010029098 Neoplasm skin Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- 150000001356 alkyl thiols Chemical class 0.000 claims 1
- PTJNLVIILOMOGI-UHFFFAOYSA-N benzyl 2-[4-[2-fluoro-5-[(4-oxo-2,3-dihydro-1,8-naphthyridin-1-yl)oxy]benzoyl]piperazine-1-carbonyl]pyrrolidine-1-carboxylate Chemical compound C(C1=CC=CC=C1)OC(=O)N1C(CCC1)C(=O)N1CCN(CC1)C(C1=C(C=CC(=C1)ON1CCC(C2=CC=CN=C12)=O)F)=O PTJNLVIILOMOGI-UHFFFAOYSA-N 0.000 claims 1
- RSEPHCRIRACQML-UHFFFAOYSA-N benzyl piperidine-2-carboxylate Chemical compound C1CCCNC1C(=O)OCC1=CC=CC=C1 RSEPHCRIRACQML-UHFFFAOYSA-N 0.000 claims 1
- DMFIILJDODEYHQ-UHFFFAOYSA-N benzyl piperidine-3-carboxylate Chemical compound C1CCNCC1C(=O)OCC1=CC=CC=C1 DMFIILJDODEYHQ-UHFFFAOYSA-N 0.000 claims 1
- BLBHAAHASZMYPI-UHFFFAOYSA-N benzyl piperidine-4-carboxylate Chemical compound C1CNCCC1C(=O)OCC1=CC=CC=C1 BLBHAAHASZMYPI-UHFFFAOYSA-N 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 208000019420 lymphoid neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- IVXQBCUBSIPQGU-UHFFFAOYSA-N piperazine-1-carboxamide Chemical compound NC(=O)N1CCNCC1 IVXQBCUBSIPQGU-UHFFFAOYSA-N 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 208000028466 reproductive system neoplasm Diseases 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110390364 | 2011-11-30 | ||
| PCT/CN2012/001611 WO2013078771A1 (zh) | 2011-11-30 | 2012-12-03 | 一种多聚（adp-核糖）聚合酶抑制剂 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015500212A JP2015500212A (ja) | 2015-01-05 |
| JP2015500212A5 true JP2015500212A5 (enExample) | 2015-03-26 |
| JP5820081B2 JP5820081B2 (ja) | 2015-11-24 |
Family
ID=48491227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014543747A Active JP5820081B2 (ja) | 2011-11-30 | 2012-12-03 | ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9187430B2 (enExample) |
| EP (1) | EP2799435B1 (enExample) |
| JP (1) | JP5820081B2 (enExample) |
| CN (1) | CN103130723B (enExample) |
| CA (1) | CA2857405C (enExample) |
| WO (1) | WO2013078771A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103130723B (zh) * | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| CN102898377B (zh) * | 2012-02-14 | 2016-01-20 | 南京圣和药业股份有限公司 | 一类酞嗪酮衍生物及其用途 |
| EP3587406B1 (en) | 2013-03-13 | 2021-01-27 | Forma Therapeutics, Inc. | 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer |
| KR101670126B1 (ko) | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
| CN105017140B (zh) * | 2014-04-28 | 2017-12-29 | 复旦大学 | 邻氨基苯甲酰胺化合物及其制备方法和用途 |
| WO2015179559A2 (en) * | 2014-05-21 | 2015-11-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| CN105777651A (zh) * | 2015-01-13 | 2016-07-20 | 江苏豪森药业集团有限公司 | 聚腺苷酸二磷酸核糖转移酶抑制剂的晶型及其制备方法和医药用途 |
| WO2017087854A1 (en) * | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| US10385057B2 (en) | 2015-11-20 | 2019-08-20 | Lundbeck La Jolla Research Center, Inc. | Pyrazole compounds and methods of making and using same |
| US10323038B2 (en) | 2015-11-20 | 2019-06-18 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| WO2017096315A1 (en) | 2015-12-02 | 2017-06-08 | The Scripps Research Institute | TRIAZOLE DAGL(α) INHIBITORS |
| CN107955001A (zh) * | 2016-10-14 | 2018-04-24 | 上海汇伦生命科技有限公司 | 抗肿瘤杂环并咪唑类化合物的药用盐 |
| CN106946792B (zh) * | 2017-03-29 | 2019-07-26 | 深圳市坤健创新药物研究院 | 一种酞嗪酮的异羟肟酸衍生物及其制备方法与应用 |
| CN107082764B (zh) * | 2017-05-23 | 2018-11-02 | 上海锐聚恩新药研发有限公司 | 一类多羟基酞嗪酮化合物、其制备方法及应用 |
| US10266497B2 (en) | 2017-05-23 | 2019-04-23 | Abide Therapeutics, Inc. | Pyrazole MAGL inhibitors |
| US10927105B1 (en) | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
| JOP20190267A1 (ar) | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | مثبطات بيرازول magl |
| WO2019224783A1 (en) | 2018-05-24 | 2019-11-28 | Novartis Ag | Automatic drug delivery device |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| TWI884745B (zh) | 2018-10-12 | 2025-05-21 | 美商拓臻股份有限公司 | 甲狀腺素受體β促效劑化合物 |
| CN113382633A (zh) | 2018-10-29 | 2021-09-10 | 福马治疗股份有限公司 | (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式 |
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| EP4017875A4 (en) | 2019-08-23 | 2023-05-03 | Terns Pharmaceuticals, Inc. | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS |
| AU2020346057A1 (en) * | 2019-09-12 | 2022-04-21 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CA3176219A1 (en) | 2020-04-21 | 2021-10-28 | Kunhee LEE | Crystalline forms of phthalazinone compound |
| JP7626783B2 (ja) | 2020-04-21 | 2025-02-07 | アイディーエンス カンパニー リミテッド | フタラジノン誘導体及びその中間体を調製するプロセス |
| CN111732844A (zh) * | 2020-07-08 | 2020-10-02 | 高雪梅 | 一种家居防火涂料及其制备方法 |
| US12059419B2 (en) | 2020-10-16 | 2024-08-13 | Idience Co., Ltd. | Pharmaceutical composition comprising phthalazinone derivatives |
| EP4387966A4 (en) * | 2021-08-17 | 2026-02-11 | Inventisbio Co Ltd | PYRIDAZINONE OR PYRIDINONE COMPOUNDS, THEIR PREPARATION PROCESSES AND THEIR USES |
| WO2023192864A2 (en) * | 2022-03-28 | 2023-10-05 | Oregon Health & Science University | Covalent parp16 inhibitors |
| US20260055079A1 (en) * | 2022-04-01 | 2026-02-26 | Azkarra Therapeutics, Inc. | Phthalazinone compounds as parp7 inhibitors |
| WO2024146631A1 (zh) * | 2023-01-06 | 2024-07-11 | 齐鲁制药有限公司 | 一种parp7抑制剂的制备方法 |
| WO2024211898A1 (en) | 2023-04-07 | 2024-10-10 | Terns Pharmaceuticals, Inc. | Combination comprising a thrbeta agonist anda glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| KR100447539B1 (ko) * | 1995-08-02 | 2004-11-10 | 뉴캐슬 유니버시티 벤처스 리미티드 | 벤조이미다졸화합물과이를포함하는제약학적조성물및이화합물을이용한치료방법 |
| US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| NZ511825A (en) | 1998-11-27 | 2003-08-29 | Basf Ag | Substituted benzimidazoles and their use as parp inhibitors |
| DE19921567A1 (de) | 1999-05-11 | 2000-11-16 | Basf Ag | Verwendung von Phthalazine-Derivaten |
| US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| HU228960B1 (hu) | 2000-10-30 | 2013-07-29 | Kudos Pharm Ltd | Ftalazinon-származékok |
| GB0026505D0 (en) * | 2000-10-30 | 2000-12-13 | Kudos Pharm Ltd | Phthalazinone derivatives |
| ITMI20002358A1 (it) | 2000-10-31 | 2002-05-01 | Flavio Moroni | Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi |
| CA2456985A1 (en) * | 2001-08-15 | 2003-02-27 | Icos Corporation | 2h-phthalazin-1-ones and methods for use thereof |
| AUPS019702A0 (en) | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
| AU2003229953A1 (en) * | 2002-04-30 | 2003-11-17 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| WO2003103666A2 (en) | 2002-06-07 | 2003-12-18 | Altana Pharma Ag | Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones |
| DK1557414T3 (da) | 2002-10-01 | 2012-05-29 | Mitsubishi Tanabe Pharma Corp | IsoquinoIin-forbindelser og medicinsk anvendelse deraf |
| GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
| BRPI0408284B8 (pt) | 2003-03-12 | 2021-05-25 | Kudos Pharm Ltd | compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| HU227948B1 (en) | 2003-04-30 | 2012-07-30 | Pecsi Tudomanyegyetem | Quinazoline derivatives and their use for the preparation of pharmaceutical compositions inhibiting parp enzyme |
| AU2004270187A1 (en) | 2003-09-04 | 2005-03-17 | Aventis Pharmaceuticals Inc. | Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) |
| CN1905864B (zh) | 2003-12-01 | 2011-04-06 | 库多斯药物有限公司 | 用于治疗癌症的dna损伤修复抑制剂 |
| WO2005053662A1 (en) | 2003-12-01 | 2005-06-16 | Kudos Pharmaceuticals Limited | Dna damage repair inhibitors for treatment of cancer |
| SG151249A1 (en) | 2003-12-05 | 2009-04-30 | Janssen Pharmaceutica Nv | 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| CN1980913B (zh) | 2004-06-30 | 2011-12-14 | 詹森药业有限公司 | 作为parp抑制剂的喹唑啉二酮衍生物 |
| GB0419072D0 (en) * | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| MX2007002318A (es) | 2004-08-26 | 2007-04-17 | Kudos Pharm Ltd | Derivados de ftalazinona substituidos con 4-heteroarilmetilo. |
| PL1794163T3 (pl) | 2004-09-22 | 2010-06-30 | Pfizer | Sposób wytwarzania inhibitorów poli(adp-rybozo)polimerazy |
| GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| CA2652167A1 (en) | 2006-05-31 | 2007-12-06 | Philip Jones | Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase (parp) |
| GB0615809D0 (en) | 2006-08-09 | 2006-09-20 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| AR070221A1 (es) * | 2008-01-23 | 2010-03-25 | Astrazeneca Ab | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. |
| ES2454567T3 (es) * | 2010-04-16 | 2014-04-10 | Abbvie Inc. | Inhibidores de quinasas ftalazin-(2h)-ona |
| US8871765B2 (en) | 2010-07-27 | 2014-10-28 | Cadila Healthcare Limited | Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as poly (ADP-ribose) polymerase-1 inhibitors |
| CN102485721B (zh) | 2010-12-03 | 2015-12-09 | 曹亚 | 取代的2,3-二氮杂萘酮化合物及其用途 |
| CN103130723B (zh) * | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| CN102898377B (zh) * | 2012-02-14 | 2016-01-20 | 南京圣和药业股份有限公司 | 一类酞嗪酮衍生物及其用途 |
-
2012
- 2012-11-30 CN CN201210504537.2A patent/CN103130723B/zh active Active
- 2012-12-03 JP JP2014543747A patent/JP5820081B2/ja active Active
- 2012-12-03 US US14/361,698 patent/US9187430B2/en active Active
- 2012-12-03 WO PCT/CN2012/001611 patent/WO2013078771A1/zh not_active Ceased
- 2012-12-03 EP EP12852659.7A patent/EP2799435B1/en active Active
- 2012-12-03 CA CA2857405A patent/CA2857405C/en active Active
-
2015
- 2015-08-13 US US14/826,181 patent/US9718787B2/en active Active